The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Advantages and Challenges of Using Endolysins in a Clinical Setting
Open accessAbstract
Antibiotic-resistant pathogens are increasingly more prevalent and problematic. Traditional antibiotics are no longer a viable option for dealing with these multidrug-resistant microbes and so new approaches are needed. Bacteriophage-derived proteins such as endolysins could offer one effective solution. Endolysins are bacteriophage-encoded peptidoglycan hydrolases that act to lyse bacterial cells by targeting their cell’s wall, particularly in Gram-positive bacteria due to their naturally exposed peptidoglycan layer. These lytic enzymes have received much interest from the scientific community in recent years for their specificity, mode of action, potential for engineering, and lack of resistance mechanisms. Over the past decade, a renewed interest in endolysin therapy has led to a number of successful applications. Recombinant endolysins have been shown to be effective against prominent pathogens such as MRSA, Listeria monocytogenes, Staphylococcus strains in biofilm formation, and Pseudomonas aeruginosa. Endolysins have also been studied in combination with other antimicrobials, giving a synergistic effect. Although endolysin therapy comes with some regulatory and logistical hurdles, the future looks promising, with the emergence of engineered “next-generation” lysins. This review will focus on the likelihood that endolysins will become a viable new antimicrobial therapy and the challenges that may have to be overcome along the way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Antibiotics: past, present and future
Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.10.008 · Cited by 2,370
Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin
Waldor, M. K., & Mekalanos, J. J. (1996) · Science · doi:10.1126/science.272.5270.1910 · Cited by 1,879
Origins and evolution of antibiotic resistance.
DAVIES, J. E. (1996) · PubMed · Cited by 1,033
Langdon, A., Crook, N., & Dantas, G. (2016) · Genome Medicine · doi:10.1186/s13073-016-0294-z · Cited by 912
From bacterial killing to immune modulation: Recent insights into the functions of lysozyme
Ragland, S. A., & Criss, A. K. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006512 · Cited by 877
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 823
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754
Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth
Hyman, P. (2019) · Pharmaceuticals · doi:10.3390/ph12010035 · Cited by 546
Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
Principi, N., Silvestri, E., & Esposito, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00513 · Cited by 454
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
The lung as a route for systemic delivery of therapeutic proteins and peptides
Uchenna Agu, R., Ikechukwu Ugwoke, M., Armand, M., Kinget, R., & Verbeke, N. (2001) · Respiratory Research · doi:10.1186/rr58 · Cited by 411
Nasal Delivery of High Molecular Weight Drugs
Ozsoy, Y., Gungor, S., & Cevher, E. (2009) · Molecules · doi:10.3390/molecules14093754 · Cited by 242
Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., & Fischetti, V. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01625-09 · Cited by 233
Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., Yagyu, K., Muraoka, A., Sugai, M., Hiramatsu, K., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521305 · Cited by 232
Recombinant bacteriophage lysins as antibacterials
Fenton, M., McAuliffe, O., O’Mahony, J., & Coffey, A. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.1.9818 · Cited by 225
Haddad Kashani, H., Schmelcher, M., Sabzalipoor, H., Seyed Hosseini, E., & Moniri, R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00071-17 · Cited by 225
A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa
Guo, M., Feng, C., Ren, J., Zhuang, X., Zhang, Y., Zhu, Y., Dong, K., He, P., Guo, X., & Qin, J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00293 · Cited by 190
Briers, Y., & Lavigne, R. (2015) · Future Microbiology · doi:10.2217/fmb.15.8 · Cited by 189
Development of Phage Lysins as Novel Therapeutics: A Historical Perspective
Fischetti, V. A. (2018) · Viruses · doi:10.3390/v10060310 · Cited by 185
Jun, S. Y., Jang, I. J., Yoon, S., Jang, K., Yu, K.-S., Cho, J. Y., Seong, M.-W., Jung, G. M., Yoon, S. J., & Kang, S. H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02629-16 · Cited by 184
Contribution of the Immune Response to Phage Therapy
Krut, O., & Bekeredjian-Ding, I. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701745 · Cited by 172
Totté, J. E. E., van Doorn, M. B., & Pasmans, S. G. M. A. (2017) · Case Reports in Dermatology · doi:10.1159/000473872 · Cited by 161
Mayer, M. J., Narbad, A., & Gasson, M. J. (2008) · Journal of Bacteriology · doi:10.1128/jb.00686-08 · Cited by 158
Cha, Y., Son, B., & Ryu, S. (2019) · Food Microbiology · doi:10.1016/j.fm.2019.103245 · Cited by 148
Thandar, M., Lood, R., Winer, B. Y., Deutsch, D. R., Euler, C. W., & Fischetti, V. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02972-15 · Cited by 145
Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?
Gutiérrez, D., Fernández, L., Rodríguez, A., & García, P. (2018) · mBio · doi:10.1128/mbio.01923-17 · Cited by 139
Żaczek, M., Łusiak-Szelachowska, M., Jończyk‐Matysiak, E., Weber‐Dąbrowska, B., Międzybrodzki, R., Owczarek, B., Kopciuch, A., Fortuna, W., Rogóż, P., & Górski, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01681 · Cited by 134
Characterization of LysB4, an endolysin from the Bacillus cereus-infecting bacteriophage B4
Son, B., Yun, J., Lim, J.-A., Shin, H., Heu, S., & Ryu, S. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-33 · Cited by 129
Enzybiotics: Enzyme-Based Antibacterials as Therapeutics
Dams, D., & Briers, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7709-9_11 · Cited by 127
From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria
Gerstmans, H., Rodríguez‐Rubio, L., Lavigne, R., & Briers, Y. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150192 · Cited by 121
Heselpoth, R. D., Euler, C. W., Schuch, R., & Fischetti, V. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00342-19 · Cited by 116
Yang, H., Linden, S. B., Wang, J., Yu, J., Nelson, D. C., & Wei, H. (2015) · Scientific Reports · doi:10.1038/srep17257 · Cited by 110
Jun, S. Y., Jung, G. M., Yoon, S. J., Choi, Y., Koh, W. S., Moon, K., & Kang, S. H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02232-13 · Cited by 102
An Unsupported Preference for Intravenous Antibiotics
Li, H. K., Agweyu, A., English, M., & Bejon, P. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001825 · Cited by 92
Hathaway, H. J., Ajuebor, J., Stephens, L. J., Coffey, A., Potter, U., Sutton, J. M., & Jenkins, A. T. A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.030 · Cited by 90
Yang, H., Zhang, H., Wang, J., Yu, J., & Wei, H. (2017) · Scientific Reports · doi:10.1038/srep40182 · Cited by 88
Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal
Harhala, M. A., Nelson, D. C., Miernikiewicz, P., Heselpoth, R. D., Brzezicka, B., Majewska, J., Linden, S. B., Shang, X., Szymczak, A., Lecion, D., et al. (2018) · Viruses · doi:10.3390/v10110638 · Cited by 68
Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes
Portilla, S., Fernández, L., Gutiérrez, D., Rodríguez, A., & García, P. (2020) · Antibiotics · doi:10.3390/antibiotics9050242 · Cited by 63
The small-molecule antibiotics pipeline: 2014–2018
Lepore, C. J., Silver, L. L., Theuretzbacher, U., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00130-8 · Cited by 62
Zhang, Y., Cheng, M., Zhang, H., Dai, J., Guo, Z., Li, X., Ji, Y., Cai, R., Xi, H., Wang, X., et al. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.00886-18 · Cited by 57
Rodríguez‐Rubio, L., Martínez, B., Rodríguez, A., Donovan, D. M., Götz, F., & García, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064671 · Cited by 56
Rusinov, I., Ershova, A. S., Karyagina, A. S., Spirin, S., & Alexeevski, A. V. (2018) · BMC Genomics · doi:10.1186/s12864-018-5324-3 · Cited by 54
Bacteriophage Endolysins and their Applications
Ajuebor, J., McAuliffe, O. E., O’Mahony, J., Ross, R. P., Hill, C., & Coffey, A. (2016) · Science Progress · doi:10.3184/003685016x14627913637705 · Cited by 48
Self-citationWatson, A., Oh, J. T., Sauve, K., Bradford, P. A., Cassino, C., & Schuch, R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01078-19 · Cited by 46
Wang, S., Gu, J., Lv, M., Guo, Z., Yan, G., Yu, L., Du, C., Feng, X., Han, W., Sun, C., et al. (2017) · The Journal of Microbiology · doi:10.1007/s12275-017-6431-6 · Cited by 44
Proença, D., Leandro, C., García, M., Pimentel, M., & São‐José, C. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6483-7 · Cited by 30
Chen, H., Su, P.-Y., Kuo, S., Lauderdale, T.-L. Y., & Shih, C. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01440 · Cited by 25
Is Genetic Mobilization Considered When Using Bacteriophages in Antimicrobial Therapy?
Rodríguez‐Rubio, L., Jofre, J., & Muniesa, M. (2017) · Antibiotics · doi:10.3390/antibiotics6040032 · Cited by 17
Cited by
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111615 · Cited by 1,215
Elfadadny, A., Ragab, R. F., AlHarbi, M., Badshah, F., Ibáñez-Arancibia, E., Farag, A., Hendawy, A. O., De los Ríos-Escalante, P. R., Aboubakr, M., Zakai, S. A., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374466 · Cited by 340
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms
Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114
Kim, K., Jang, H., Kim, E., Kim, H., & Sung, G. Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14940 · Cited by 24
Metadata
- Authors
- Murray, E., Draper, L. A., Ross, R. P., & Hill, C.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-04-15
- Volume
- 13
- Issue
- 4
- Pages
- 680
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3152895331
- Cited by
- 263
- References
- 52
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.